Medical device maker Keyron today announced the appointment of three new directors to its board—including the former Director of the FDA’s Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders.
These appointments arrives as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. The implant is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a minimally invasive procedure.
Board Appointments
- David Feigal MD (Head of Regulatory Affairs) – Former Director of the FDA’s Center for Devices and Radiological Health (CDRH). Covered the highest role and authority in medical devices at the FDA. Brings decades of experience guiding breakthrough technologies through FDA approval and will now be the Company’s lead for FDA engagement and IDE submission. Founder of leading U.S. regulatory consultancy, NDA Partners. Widely recognized as one of the most experienced regulatory experts in the U.S., he has held senior global roles at public companies Amgen and Elan and led or advised over 20 successful medical product approvals across therapeutic areas.
- Joyce Peetermans, Ph.D. (Acting CTO) – More than 35 years of leadership roles in R&D, Clinical Research, and Innovation in Gastroenterological and Surgical Endoscopy, and other specialties. She spent 25 years at Boston Scientific, where she was on the Endoscopy Management Board as VP of Global Clinical Programs, and VP of Innovation and Research during the $615M acquisition of Apollo Endosurgery and several other key acquisitions by Boston Scientific Endoscopy.
- Christopher Rowland (Chairman) – A seasoned executive with over 35 years leading Class III endoscopic and metabolic device companies. He served as President at Given Imaging prior to its $860 million PillCam exit to Covidien (Medtronic) and was CEO of Neotract before its $1.1 billion acquisition by Teleflex. He also spent 17 years in senior roles at Boston Scientific. Christopher will chair Keyron’s board of directors and support its corporate development and fundraising strategy.
This leadership expansion follows several large-animal studies of ForePass demonstrating safety, tolerability, and efficacy on both weight and insulin production. The company is now preparing to unveil preclinical data showing apparent superiority over Semaglutide—the standard of care for obesity and diabetes in Ozempic and Wegovy—across all major endpoints. These data are expected to be published this summer.
Keyron, a VC-backed startup, has developed a proprietary biometabolic implant and endoscopic delivery system, secured clinical sites in the U.S. and internationally, and completed long-term preclinical validation. The company is now preparing for its First-In-Human study.
